{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:28:32Z","timestamp":1793694512926,"version":"4.5.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Le1030\/15-2"],"award-info":[{"award-number":["Le1030\/15-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["493665037"],"award-info":[{"award-number":["493665037"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["01GM2201A"],"award-info":[{"award-number":["01GM2201A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.phrs.2026.109651","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:03:13Z","timestamp":1790434993000},"page":"109651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Differential effects of sodium channel blockers on SCN8A gain-of-function variants associated with drug-responsive or -resistant epilepsy"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1107-4297","authenticated-orcid":false,"given":"Hang","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Previtali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine M.","family":"Johannesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Bo\u00dfelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke S.","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Lerche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.109651_bib1","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1093\/brain\/awab321","article-title":"Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications","volume":"145","author":"Johannesen","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.109651_bib2","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1111\/epi.17747","article-title":"Clinical severity is correlated with age at seizure onset and biophysical properties of recurrent gain of function variants associated with SCN8A-related epilepsy","volume":"64","author":"Chung","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2026.109651_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/epd2.20026","article-title":"ILAE Genetics Commission. ILAE Genetic Literacy Series: Self-limited familial epilepsy syndromes with onset in neonatal age and infancy","volume":"25","author":"Millevert","year":"2023","journal-title":"Epileptic Disord."},{"issue":"5","key":"10.1016\/j.phrs.2026.109651_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ejpn.2016.04.015","article-title":"Autosomal dominant SCN8A mutation with an unusually mild phenotype","volume":"20","author":"Anand","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.phrs.2026.109651_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ana.24580","article-title":"Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation","volume":"79","author":"Gardella","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2026.109651_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/brain\/awy326","article-title":"Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability","volume":"142","author":"Liu","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.109651_bib7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/epi.14705","article-title":"The spectrum of intermediate SCN8A-related epilepsy","volume":"60","author":"Johannesen","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2026.109651_bib8","doi-asserted-by":"crossref","first-page":"e1112","DOI":"10.1212\/WNL.0000000000006199","article-title":"The phenotype of SCN8A developmental and epileptic encephalopathy","volume":"91","author":"Gardella","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2026.109651_bib9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/jmedgenet-2014-102813","article-title":"De novo gain-of-function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy","volume":"52","author":"Blanchard","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.phrs.2026.109651_bib10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/acn3.276","article-title":"Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy","volume":"3","author":"Wagnon","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.phrs.2026.109651_bib11","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2026.109651_bib12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/epi.12668","article-title":"Early onset epileptic encephalopathy caused by de novo SCN8A mutations","volume":"55","author":"Ohba","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2026.109651_bib13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bph.12534","article-title":"Properties of human brain sodium channel \u03b1-subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine","volume":"171","author":"Qiao","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109651_bib14","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0026-895X(24)13073-8","article-title":"A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels","volume":"54","author":"Kuo","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109651_bib15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0026-895X(25)09804-9","article-title":"Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons","volume":"46","author":"Kuo","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109651_bib16","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1124\/mol.51.6.1077","article-title":"Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications","volume":"51","author":"Kuo","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109651_bib17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bph.15981","article-title":"vitro effects of eslicarbazepine (S-licarbazepine) as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders","volume":"180","author":"Bayraktar","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109651_bib18","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/epi.14196","article-title":"The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy","volume":"59","author":"Baker","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2026.109651_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107699","article-title":"Prax330 reduces persistent and resurgent sodium channel currents and neuronal hyperexcitability of subiculum neurons in a mouse model of SCN8A epileptic encephalopathy","volume":"158","author":"Wengert","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2026.109651_bib20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/brain\/awy324","article-title":"Prominent role of forebrain excitatory neurons in SCN8A encephalopathy","volume":"142","author":"Bunton-Stasyshyn","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.109651_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nbd.2014.05.017","article-title":"A novel de novo mutation of SCN8A (Nav1.6) with enhanced channel activation in a child with epileptic encephalopathy","volume":"69","author":"Estacion","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.109651_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1113\/JP278952","article-title":"Distinct functional alterations in SCN8A epilepsy mutant channels","volume":"598","author":"Pan","year":"2020","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2026.109651_bib23","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/epi.13461","article-title":"The SCN8A encephalopathy mutation p.Ile1327Val displays elevated sensitivity to the anticonvulsant phenytoin","volume":"57","author":"Barker","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2026.109651_bib24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ajhg.2012.01.006","article-title":"De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP","volume":"90","author":"Veeramah","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.phrs.2026.109651_bib25","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1038\/s41401-022-00955-x","article-title":"SCN8A epileptic encephalopathy mutations display a gain-of-function phenotype and divergent sensitivity to antiepileptic drugs","volume":"43","author":"Guo","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.phrs.2026.109651_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2026.109651_bib27","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/epi.18338","article-title":"Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy","volume":"66","author":"Beniczky","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2026.109651_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104855","article-title":"Clinical and electrophysiological features of SCN8A variants causing episodic or chronic ataxia","volume":"98","author":"Lyu","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2026.109651_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eplepsyres.2017.10.017","article-title":"Early-onset epileptic encephalopathy with de novo SCN8A mutation","volume":"139","author":"Xiao","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.phrs.2026.109651_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1124\/mol.116.103358","article-title":"Use-Dependent Block of Human Cardiac Sodium Channels by GS967","volume":"90","author":"Potet","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109651_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.seizure.2022.03.008","article-title":"Clinical characteristics and treatment experience of individuals with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE): Findings from an online caregiver survey","volume":"97","author":"Cutts","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.phrs.2026.109651_bib32","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2026.109651_bib33","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3389\/fphar.2020.01276","article-title":"Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review","volume":"11","author":"Menezes","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109651_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106824","article-title":"A SCN8A variant associated with severe early onset epilepsy and developmental delay: Loss- or gain-of-function?","volume":"178","author":"Liu","year":"2021","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.phrs.2026.109651_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.112.198887","article-title":"A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias","volume":"344","author":"Belardinelli","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2026.109651_bib36","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.hrthm.2013.03.023","article-title":"Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967","volume":"10","author":"Sicouri","year":"2013","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.phrs.2026.109651_bib37","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3390\/ijms21072454","article-title":"Differential Inhibition of Human Nav1.2 Resurgent and Persistent Sodium Currents by Cannabidiol and GS967","volume":"21","author":"Mason","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.109651_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s10194-019-1056-2","article-title":"Late sodium current blocker GS967 inhibits persistent currents induced by familial hemiplegic migraine type 3 mutations of the SCN1A gene","volume":"20","author":"Barbieri","year":"2019","journal-title":"J. Headache Pain."},{"key":"10.1016\/j.phrs.2026.109651_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142202","article-title":"Hyperexcitable interneurons trigger cortical spreading depression in an Scn1a migraine model","volume":"131","author":"Auffenberg","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2026.109651_bib40","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/epi.12657","article-title":"Antiepileptic activity of preferential inhibitors of persistent sodium current","volume":"55","author":"Anderson","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2026.109651_bib41","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00424-024-02980-7","article-title":"Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers","volume":"476","author":"M\u00fcller","year":"2024","journal-title":"Pflug. Arch."},{"key":"10.1016\/j.phrs.2026.109651_bib42","doi-asserted-by":"crossref","unstructured":"Kahlig K.M., Chapman M., Petrou S. PRAX-628: A Novel Sodium Channel Blocker with Greater Potency and Activity Dependence Compared to Standard of Care, Boston, USA: 2023.","DOI":"10.1212\/WNL.0000000000203120"},{"key":"10.1016\/j.phrs.2026.109651_bib43","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/molpharm.120.000048","article-title":"GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes","volume":"98","author":"Potet","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109651_bib44","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/epi.17149","article-title":"The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers","volume":"63","author":"Kahlig","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2026.109651_bib45","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.72468","article-title":"NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats","volume":"11","author":"Johnson","year":"2022","journal-title":"Elife"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826015665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826015665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:02:09Z","timestamp":1793692929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826015665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":45,"alternative-id":["S1043661826015665"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.109651","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential effects of sodium channel blockers on SCN8A gain-of-function variants associated with drug-responsive or -resistant epilepsy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.109651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109651"}}